Vermillion Gets Permits to Open Clinical Reference Laboratory | GenomeWeb

NEW YORK (GenomeWeb News) – Vermillion said today that it has obtained permits and completed regulatory processes required for opening a clinical reference laboratory.

In a filing with the US Securities and Exchange Commission, the company said that the lab, Aspira Labs, "will offer tests related to gynecologic oncology and women’s health," including its OVA1 ovarian cancer test.

The lab will be led by Herbert Fritsche, formerly clinical chemistry section chief in the Department of Pathology and Laboratory Medicine at MD Anderson Cancer Center.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.